Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
falimarev + inalimarev + sargramostim
- Development stage
- Phase 2
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This is a combination immunotherapy regimen consisting of two therapeutic cancer vaccines, falimarev (PANVAC-F) and inalimarev (PANVAC-V), administered together with sargramostim. Falimarev and inalimarev are recombinant poxvirus-based vaccines engineered to express tumor-associated antigens such as carcinoembryonic antigen (CEA) and mucin-1 (MUC1), along with costimulatory molecules to enhance immune response. Sargramostim is a yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that acts as an immunomodulator by stimulating the production and function of white blood cells, thereby augmenting the immune response elicited by the vaccines. This combination has been investigated primarily for use in advanced or metastatic cancers, including colorectal cancer and pancreatic cancer[1][6][9].
- Other names
- PANVAC + sargramostimPANVAC-F + PANVAC-V + sargramostim
02
Targets
CEA-pMHC (Carcinoembryonic antigen-derived peptide-MHC complex)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)pMHC-I (Peptide–MHC class I complex)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on falimarev + inalimarev + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on falimarev + inalimarev + sargramostim.